Abarca & Amgen Enter Outcome-Based Agreement For Enbrel

The agreement reduces the cost of commercial health plans for members who discontinue treatment.

AVENTURA, FL — Abarca, a pharmacy benefit manager (PBM) that is disrupting the industry with an entirely new approach to technology and business practices, today announced it has entered into an outcomes-based contract with Amgen (NASDAQ: AMGN) for the drug Enbrel® (etanercept). Under the agreement, Amgen will issue rebates to Abarca’s clients for eligible members who discontinue the use of the drug after three months of treatment. This applies to members of commercial health plans who are using the drug to treat moderate to severe rheumatoid arthritis.

“This is a win for all parties,” said Jason Borschow, president and CEO of Abarca. “It will provide Amgen valuable information about how Enbrel® is utilized, it will lower costs for plans, and it will bring additional benefits to our healthcare system.”

Drugs that treat auto-immune conditions are the fastest-growing segment for commercial health plans. Enbrel® is a biologic medicine used to treat five inflammatory diseases and is one of the most highly utilized specialty drugs for this market.

Outcome-based agreements have been a hot topic in the healthcare industry for several years. However, because most PBMs do not have the technology to track and report when a member discontinues a drug, relatively few have been implemented. The agreement announced today was made possible by Darwin, Abarca’s more innovative PBM platform, which tracks utilization in real-time and generates the detailed information drug makers need to issue a rebate.

This is the second outcome-based between Abarca and Amgen. In 2018, the companies entered into an arrangement for Repatha–the first agreement of its kind involving Repatha. That same year, Abarca announced an outcomes-based contract with Biogen for medications used to treat multiple sclerosis.

“Amgen has been a great partner,” continued Borschow. “Their dedication to learning about how patients interact with their medications is admirable, and we look forward to continuing to work together to find new approaches to serve our clients and members.”

Abarca is currently collaborating with several drug manufacturers for similar agreements.

DuartePino is a management advisory firm that combines in-depth customer knowledge with practical expertise in marketing to help clients create sustainable business growth. We can provide your organization with a fresh perspective, a proven process that invests in the outcome, and the tools for successful execution. From Fractional CMOs to business advisors, contact us to learn how our team can help with growth strategies for your organization.